Dyne Therapeutics, Inc.
DYNNASDAQHealthcare● Active
$16.81
$-0.23(-1.35%)
Market Cap$2.8B
P/E Ratio—
52W High$25
52W Low$8.06
Dyne Therapeutics, Inc. (DYN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DYN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.73
Est. -$0.77 · +5.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
DYN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 27, 2026 | -$0.74 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.77 | -$0.73 | +5.5% | — | — | — |
| ▼ Q1 FY2026 | Mar 2, 2026 | -$0.74 | -$0.76 | -2.7% | — | — | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.81 | -$0.76 | +6.2% | — | — | — |
| ▲ Q3 FY2025 | Jul 28, 2025 | -$0.99 | -$0.97 | +2.0% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.88 | -$1.05 | -19.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.92 | -$0.88 | +4.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.71 | -$0.96 | -35.2% | — | — | — |
Q3 FY2026
Jul 27, 2026
EPS Actual
—
EPS Est.
-$0.74
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.73
EPS Est.
-$0.77
EPS Surpr.
+5.5%
Revenue
—
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
-$0.76
EPS Est.
-$0.74
EPS Surpr.
-2.7%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.76
EPS Est.
-$0.81
EPS Surpr.
+6.2%
Revenue
—
Q3 FY2025
Jul 28, 2025Beat
EPS Actual
-$0.97
EPS Est.
-$0.99
EPS Surpr.
+2.0%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$1.05
EPS Est.
-$0.88
EPS Surpr.
-19.3%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.88
EPS Est.
-$0.92
EPS Surpr.
+4.3%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.96
EPS Est.
-$0.71
EPS Surpr.
-35.2%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.71 | $-0.71 | $-0.71 | 3 |
| Q3 FY2027 | $-0.72 | $-0.72 | $-0.72 | 4 |
| Q2 FY2027 | $-0.73 | $-0.73 | $-0.73 | 3 |
| Q1 FY2027 | $-0.75 | $-0.75 | $-0.75 | 3 |
| Q4 FY2026 | $-0.78 | $-0.78 | $-0.78 | 7 |
| Q3 FY2026 | $-0.81 | $-0.76 | $-0.69 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +5.5% | $17.61 | $18.46 | +4.83% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -2.7% | $15.62 | $16.15 | +3.39% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +6.2% | $21.52 | $20.90 | -2.88% |
| ▲ Q3 FY2025 | Jul 28, 2025 | +2.0% | $9.95 | $9.31 | -6.43% |
| ▼ Q2 FY2025 | May 8, 2025 | -19.3% | $9.40 | $11.30 | +20.21% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +4.3% | $13.79 | $13.17 | -4.50% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -35.2% | $28.13 | $29.33 | +4.27% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +2.8% | $43.60 | $43.07 | -1.22% |
Q2 FY2026+4.83%
Report Date
May 11, 2026
EPS Beat/Miss
+5.5%
Price Before
$17.61
Price After
$18.46
Q1 FY2026+3.39%
Report Date
Mar 2, 2026
EPS Beat/Miss
-2.7%
Price Before
$15.62
Price After
$16.15
Q4 FY2025-2.88%
Report Date
Nov 5, 2025
EPS Beat/Miss
+6.2%
Price Before
$21.52
Price After
$20.90
Q3 FY2025-6.43%
Report Date
Jul 28, 2025
EPS Beat/Miss
+2.0%
Price Before
$9.95
Price After
$9.31
Q2 FY2025+20.21%
Report Date
May 8, 2025
EPS Beat/Miss
-19.3%
Price Before
$9.40
Price After
$11.30
Q1 FY2025-4.50%
Report Date
Feb 27, 2025
EPS Beat/Miss
+4.3%
Price Before
$13.79
Price After
$13.17
Q4 FY2024+4.27%
Report Date
Nov 12, 2024
EPS Beat/Miss
-35.2%
Price Before
$28.13
Price After
$29.33
Q3 FY2024-1.22%
Report Date
Aug 12, 2024
EPS Beat/Miss
+2.8%
Price Before
$43.60
Price After
$43.07
Avg Beat Reaction-2.04%
Avg Miss Reaction+9.29%
Beat Rate5 / 8 quarters
Largest Move+20.21% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DYN ends December
Dyne Therapeutics, Inc. (DYN) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.73 — beating the analyst consensus of $-0.77 by +5.5%. The next DYN earnings date is expected around September 1, 2026.
Each quarter, investors track DYN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DYN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DYN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DYN earnings · 5 questionsDyne Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DYN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DYN historically reports after market close (AMC).
DYN earnings datewhen is DYN earningsDYN next earnings datewhen does DYN report earningsDYN earnings calendar
▸ Source: FMP · Dyne Therapeutics, Inc. SEC filings · US GAAP · Dyne Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026